BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 432371)

  • 1. Increased serum methadone levels in humans during naloxone-precipitated withdrawal [proceedings].
    Resnick RB; Washton A; Verebey K; Mule SJ
    Psychopharmacol Bull; 1979 Apr; 15(2):42-4. PubMed ID: 432371
    [No Abstract]   [Full Text] [Related]  

  • 2. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1988 Aug; 246(2):441-8. PubMed ID: 2457074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio.
    Bell J; Shearer J; Ryan A; Graham R; Korompay K; Rizzo S; Sindhusake D; Somogyi AA
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):146-53. PubMed ID: 19586229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of precipitated abstinence in methadone-dependent rats by delta 9-THC.
    Hine B; Torrelio M; Gershon S
    Psychopharmacol Commun; 1975; 1(3):275-83. PubMed ID: 1241452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased elevated plus maze open-arm time in mice during naloxone-precipitated morphine withdrawal.
    Hodgson SR; Hofford RS; Norris CJ; Eitan S
    Behav Pharmacol; 2008 Dec; 19(8):805-11. PubMed ID: 19020415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opiate withdrawal-induced hyposensitivity to naloxone's effects on serum luteinizing hormone in the male rat.
    Cicero TJ; Aleem A; Meyer ER; Schmoeker PF; Miller BT
    J Pharmacol Exp Ther; 1986 Sep; 238(3):1063-70. PubMed ID: 3528453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antagonist effects of nalbuphine in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    J Pharmacol Exp Ther; 1989 Mar; 248(3):929-37. PubMed ID: 2467983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circling behavior after narcotic drugs and during naloxone-precipitated abstinence in rats with unilateral nigral lesions.
    Iwamoto ET; Loh HH; Way EL
    J Pharmacol Exp Ther; 1976 Jun; 197(3):503-16. PubMed ID: 945346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers.
    Preston KL; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1987; 76():157-61. PubMed ID: 2449617
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute physical dependence in man: repeated naloxone-precipitated withdrawal after a single dose of methadone.
    Wright C; Bigelow GE; Stitzer ML
    NIDA Res Monogr; 1989; 95():395-6. PubMed ID: 2701308
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of plasma catecholamines in eliciting cardiovascular changes seen during naloxone-precipitated withdrawal in conscious, unrestrained morphine-dependent rats.
    Chang AP; Dixon WR
    J Pharmacol Exp Ther; 1990 Sep; 254(3):857-63. PubMed ID: 2395117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of morphine, methadone and heroin induced effects in mice by naloxone methiodide.
    Lewanowitsch T; Miller JH; Irvine RJ
    Life Sci; 2006 Jan; 78(7):682-8. PubMed ID: 16102783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precipitated withdrawal by pentazocine in methadone-maintained volunteers.
    Strain EC; Preston KL; Liebson IA; Bigelow GE
    J Pharmacol Exp Ther; 1993 Nov; 267(2):624-34. PubMed ID: 7504098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings: Aversive properties of naloxone in morphine-treated rats.
    Pilcher CW; Stolerman IP
    Br J Pharmacol; 1975 Jun; 54(2):235P. PubMed ID: 1170913
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroanatomical and chemical correlates of naloxone-precipitated withdrawal.
    Way EL; Loh HH; Ho IK; Iwamoto ET; Wei E
    Adv Biochem Psychopharmacol; 1973; 8(0):455-69. PubMed ID: 4604812
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation between the in vivo and an in vitro expression of opiate withdrawal precipitated by naloxone: their antagonism by l-(-)-delta9-tetrahydrocannabinol.
    Frederickson RC; Hewes CR; Aiken JW
    J Pharmacol Exp Ther; 1976 Nov; 199(2):375-84. PubMed ID: 988178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects.
    Kanof PD; Handelsman L; Aronson MJ; Ness R; Cochrane KJ; Rubinstein KJ
    J Pharmacol Exp Ther; 1992 Jan; 260(1):355-63. PubMed ID: 1731046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in sensitivity to apomorphine during morphine dependence and withdrawal in rats.
    Cox B; Ary M; Lomax P
    J Pharmacol Exp Ther; 1976 Mar; 196(3):637-41. PubMed ID: 944260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone.
    Negus SS
    J Pharmacol Exp Ther; 2006 May; 317(2):711-23. PubMed ID: 16456085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of physical dependence in mice by naloxone-precipitated jumping after a single dose of morphine.
    Smits SE
    Res Commun Chem Pathol Pharmacol; 1975 Apr; 10(4):651-61. PubMed ID: 1171511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.